The efficacy of isotretinoin plus NB-UVB in the treatment of psoriasis vulgaris

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT138812213543N1

Enrollment

Registered

2010-04-24

Start date

2008-09-22

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriasis vulgaris. psoriasis vulgaris

Interventions

Intervention 1: Isotretinoin (0.5mg/kg) for 2 weeks then NB-UVB for 12 weeks. Intervention 2: Placebo for 2 weeks then NB-UVB for 12 weeks.

Treatment - Drugs

Placebo

Isotretinoin (0.5mg/kg) for 2 weeks then NB-UVB for 12 weeks

Placebo for 2 weeks then NB-UVB for 12 weeks

Eligibility

Sex/Gender

All

Age

15 Years to 90 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic plaque type psoriasis (psoriasis vulgaris) who are candidates for phototherapy Exclusion criteria: female patients who do not have a safe contraception or want to become pregnant in less than 1 month, patient with abnormal lipid profile tests, liver function tests and ANA

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Improvement of severity of psoriasis vulgaris. Timepoint: First visit, 4 weeks, 10 weeks, 14 weeks after starting therapy. Method of measurement: PASI score.	—

Secondary

Measure	Time frame
Complications (nausea, pruritus, erythrodermia). Timepoint: First visit, 4 weeks, 10 weeks, and 14 weeks after starting therapy. Method of measurement: clinical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSomayeh Khezri

Razi Hospital

khezri@razi.tums.ac.ir00982155609951, 00982155609952, 00982155609953

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026